睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 13 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 13

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  3. 研究中心山东省肿瘤医院Cancer Hospital, Shandong First Medical University济南医院页面
  4. 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
  5. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  6. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  7. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  8. 研究中心江苏省人民医院(南京医科大学第一附属医院)Jiangsu Provincial People's Hospital南京医院页面
  9. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  10. 研究中心汕头市中心医院Shantou Central Hospital汕头医院页面
  11. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  12. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  13. 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07003074,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology

    入选标准第 3 条

  3. Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment

    排除标准第 5 条

    Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment

    排除标准第 28 条

  4. Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1

    入选标准第 2 条

  5. Have at least one measurable lesion according to RECIST 1.1 criteria;

    入选标准第 7 条

  6. Have had or currently have other malignant tumors within the past 5 years of randomization

    排除标准第 4 条

    History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07003074,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects voluntarily enrolled in this study with good compliance
  2. Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1
  3. HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology
  4. Defined hormone receptor (HR) status
  5. Has not received systemic anti-tumor therapy during the recurrence/metastasis stage (acceptable ≤ first-line endocrine therapy)
  6. If receiving (new) adjuvant therapy, it is required that the time interval between the end of systemic therapy (excluding endocrine therapy) and the discovery of recurrence/metastasis be greater than 12 months
  7. Have at least one measurable lesion according to RECIST 1.1 criteria;
  8. Good major organ function

排除标准:Exclusion Criteria:

  1. It is known that there is spinal cord compression or active central nervous system metastasis;
  2. Subjects with only skin and/or brain lesions as target lesions
  3. Combined diseases and medical history
  4. Have had or currently have other malignant tumors within the past 5 years of randomization
  5. Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment
  6. Received major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to randomization
  7. There are diseases that affect intravenous injection and venous blood collection
  8. There are congenital bleeding and coagulation disorders present
  9. An arterial/deep vein thrombosis event occurred within 6 months prior to the first administration
  10. Poor blood pressure control
  11. Suffering from significant cardiovascular disease
  12. There is an uncontrolled infection of ≥ CTC AE grade 2 within 14 days before the start of treatment
  13. History of interstitial lung disease/pneumonia (non infectious) requiring steroid medication intervention in the past
  14. Individuals with moderate to severe pulmonary dysfunction/disease within 3 months prior to the first administration
  15. Active viral hepatitis with poor control
  16. Active syphilis infected individuals in need of treatment
  17. Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation
  18. Immunosuppressants or systemic or absorbable local hormone therapy are required to achieve immunosuppression
  19. History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases
  20. Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification>1.0 g
  21. Patients with renal failure requiring hemodialysis or peritoneal dialysis
  22. Poor control of diabetes
  23. Individuals with epilepsy who require treatment
  24. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders
  25. Tumor related symptoms and treatment
  26. There is a third interstitial fluid accumulation or cancerous lymphangitis that cannot be controlled by drainage or other methods
  27. History of cumulative dose exposure to anthracyclines in the past
  28. Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment
  29. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment
  30. Research treatment related
  31. Previously received antibody conjugate therapy consisting of topoisomerase I inhibitors,;
  32. Allergic to any research drug or any ingredient or excipient in the drug;
  33. Individuals who experience severe hypersensitivity reactions after using monoclonal antibodies;
  34. Participated in other clinical trials of anti-tumor therapy within 4 weeks before the start of the research treatment.
  35. According to the researcher's judgment, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study.

引自 ClinicalTrials.gov, NCT07003074, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07003074,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07003074